ST
STXS.US Stereotaxis Inc
- Market cap
- USD 88.9M
- P/E
- -
- P/B
- 3.79x
- ROE
- -104.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is STXS.US undervalued?
Graham numberThe Graham number of Stereotaxis Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Stereotaxis Inc fundamental analysis
No fundamental analysis for Stereotaxis Inc yet.
Stereotaxis Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Stereotaxis Inc
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System…
Full company profileStereotaxis Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Stereotaxis Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 32.2M | 31.1M | 29.3M | 28.9M | 26.6M | 35.0M | 28.1M | 26.8M | 26.9M | 32.4M | 30.5M |
| Gross Profit | 24.6M | 20.4M | 23.6M | 22.8M | 19.0M | 23.2M | 18.5M | 14.9M | 14.6M | 17.1M | 16.3M |
| Operating Income | -6.43M | -5.92M | -2.46M | -4.83M | -6.71M | -12.9M | -18.8M | -21.8M | -24.7M | -22.1M | -21.6M |
| EBITDA | -5.86M | -5.17M | -1.88M | -4.70M | -6.59M | -10.6M | -18.3M | -20.1M | -23.1M | -20.1M | -21.3M |
| Net Income | -5.29M | -5.89M | 117K | -4.23M | -6.45M | -10.7M | -19.2M | -20.7M | -24.0M | -21.6M | -22.4M |
| EPS | -0.24 | -0.26 | 0.00 | -0.07 | -0.09 | -0.14 | -0.25 | -0.26 | -0.28 | -0.24 | -0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 21.0M | 10.7M | 18.5M | 43.6M | 55.5M | 61.0M | 53.4M | 41.9M | 46.7M | 52.3M | 82.1M |
| Total Liabilities | 36.5M | 31.3M | 11.2M | 15.1M | 15.2M | 21.6M | 21.5M | 20.0M | 35.3M | 33.5M | 55.6M |
| Shareholders' Equity | -15.5M | -20.6M | 7.27M | 28.5M | 40.2M | 39.4M | 31.9M | 21.9M | 11.4M | 18.7M | 21.4M |
| Cash & Short-term Investments | 8.50M | 3.69M | 10.8M | 30.2M | 43.9M | 38.7M | 28.4M | 19.8M | 12.2M | 13.4M | 3.98M |
| Total Debt | - | - | - | 4.34M | 4.45M | 6.11M | 5.86M | 5.49M | 6.01M | 5.44M | 7.91M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.56M | -4.67M | -2.55M | -4.62M | -3.51M | -2.95M | -8.42M | -9.14M | -8.50M | -13.7M | -15.1M |
| Capital Expenditure | 410K | 81.6K | 265K | 29.5K | 70.9K | 1.40M | 2.38M | 366K | 34.0K | 93.0K | 227K |
| Free Cash Flow | -6.97M | -4.76M | -2.81M | -4.65M | -3.58M | -4.34M | -10.8M | -9.51M | -8.53M | -13.8M | -15.3M |
| Ratios | |||||||||||
| ROE | - | - | 1.6% | -14.8% | -16.0% | -27.2% | -60.0% | -94.5% | -210.3% | -115.6% | -104.9% |
| ROA | -25.2% | -55.2% | 0.6% | -9.7% | -11.6% | -17.6% | -35.9% | -49.4% | -51.5% | -41.4% | -27.3% |
| Net Profit Margin | -16.4% | -18.9% | 0.4% | -14.6% | -24.2% | -30.6% | -68.0% | -77.4% | -89.3% | -66.8% | -73.5% |
| Debt to Equity | - | - | - | 0.15x | 0.11x | 0.15x | 0.18x | 0.25x | 0.53x | 0.29x | 0.37x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Stereotaxis Inc dividends
Stereotaxis Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1096:1000 on Nov 4, 2013.
Who owns Stereotaxis Inc
- Insiders 15.10%
- Institutions 48.82%
- Public & others 36.08%
- Shares outstanding 101M
- Free float 66.5M
Stereotaxis Inc company profile
- Company name
- Stereotaxis Inc
- Ticker
- STXS.US
- Exchange
- USA Stocks
- Listed since
- Aug 12, 2004
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 131
- Fiscal year end
- December
- Address
- 710 North Tucker Boulevard, Saint Louis, MO, United States, 63101
- Phone
- 314 678 6100
- Website
- stereotaxis.com
About Stereotaxis Inc
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Stereotaxis Inc management
4- Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.CEO & Chairman · born 1987
- Ms. Kimberly R. Peery CPAChief Financial Officer · born 1969
- Mr. Keith GallowayVice President of Operations
- Ms. Patricia S. Williams Esq.General Counsel & Secretary · born 1967